Trials / Completed
CompletedNCT03521895
An Integrated Analysis of the Effectiveness of Intravitreal (IVT) Aflibercept (Eylea) in Routine Clinical Practice Based on Two Large Observational Studies
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The aim of this integrated analysis is to describe the effectiveness of Eylea in an integrated pooled analysis using existing individual patient data of two non-interventional studies RAINBOW and PERSEUS. The primary objective of this integrated analysis is to describe the effectiveness of Eylea on the mean change from baseline in visual acuity (VA) at 12 months in Wet age-related macular degeneration (wAMD) treatment naïve patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) | Patients observed with regular and irregular treatment course |
Timeline
- Start date
- 2018-05-01
- Primary completion
- 2018-11-30
- Completion
- 2018-11-30
- First posted
- 2018-05-11
- Last updated
- 2020-01-10
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT03521895. Inclusion in this directory is not an endorsement.